R&D products

After having developed Fabenflu®, a product indicated for the treatment of avian influenza (H5N1) in human, Fab’entech is currently focusing on 2 products: a candidate targeting Ebola virus having been identified by WHO as the unique therapeutic solution in Europe in 2014, and an antidote candidate in the field of bioterrorism in collaboration with the French army. Fab’entech’s pipeline will be reinforced in the next few months with new core antidote candidates.
​

ANTIDOTES

Fab’entech is going to develop a core antidotes range, leaded by the candidate currently developed in collaboration with the French army in the field of bioterrorism. 

​Antidotes include immunotherapies targeting bioterrorism threats such as anthrax, and intoxications like envenomations or drug intoxications.

SEVERE infectious diseases

Fab’entech is looking for industrial partners to co-develop emergency immunotherapies targeting severe infectious diseases. 

​Severe infectious diseases include but are not limited to nosocomial infections such as Staphylococcus aureus.

EMERGING INFECTIOUS DISEASES

After having developed Fabenflu®, a product indicated for the treatment of avian influenza (H5N1) in human, Fab’entech is currently developing an emergency immunotherapy targeting Ebola virus with the support of renowned academic partners and the European Commission under the consortium IF-Ebola. Fab’entech is also member of a public-private consortium dedicated to Crimean-Congo Hemorrhagic Fever (CCHF), with the support of BPI France & Grand Lyon. Fab'entech remains open to new collaborations with academic partners & public institutions for the development of immunotherapies indicated for the treatment of emerging infectious diseases.

​Emerging infectious diseases also include: Mers-CoV, Hendra-Nipah, Lassa, Marburg, Dengue, Yellow Fever, West Nile, SRAS, etc.